Major Depressive Disorders
14
0
0
9
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
0.0%
0 terminated out of 14 trials
100.0%
+13.5% vs benchmark
21%
3 trials in Phase 3/4
0%
0 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (14)
The Effects of Transcranial Magnetic Stimulation on Retina and Choroidal Structures
Effects of Electroacupuncture on Cognitive Symptoms in Major Depressive Disorder
N-Acetyl Cysteine Supplementation in Therapy Refractory Major Depressive Disorders
Loneliness and Occurrence of Suicide Attempts and Suicidal Ideas
Efficacy of Transcranial Direct Current Stimulation (tDCS) for the Treatment of Major Depressive Disorder
Multi-center Imaging Genetics Studies in China
MetAbolism vaRiability of VEnLafaxine
Blended Depression Therapy: Cognitive Behaviour Therapy Face-to-face and Via Internet
Relapse Predicting Model for First Episode Depression
Health Care Management for the Elderly in Community Through Screening
The Purpose of the Study is to Gain an In-depth Picture of the Patient Management and Prescription Behaviours
Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
Efficacy and Safety of One Single Dose of SR58611 Compared to Placebo and Paroxetine
Long Term Safety and Tolerability of SR58611 in Patients With Major Depressive Disorder